antineoplastic agents, alkylating

Preferred Label : antineoplastic agents, alkylating;

MeSH definition : A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026);

MeSH synonym : alkylating antineoplastics; antineoplastic alkylating drugs; antineoplastic drugs, alkylating; alkylating drugs, antineoplastic; drugs, antineoplastic alkylating; alkylating antineoplastic agents; antineoplastic alkylating agents; alkylating agents, antineoplastic; antineoplastics, alkylating; alkylating antineoplastic drugs;

Wikipedia automatic translation : Alkylating antineoplastic agent;

Wikipedia link : https://en.wikipedia.org/wiki/Alkylating antineoplastic agent;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D018906;

UMLS CUI

C0282532;

ATC code(s)
- alkyl sulfonates [ATC Code]
- alkylating agents [ATC Code]
- cyclophosphamide [ATC Code]
- epoxides [ATC Code]
- ethylene imines [ATC Code]
- melphalan [ATC Code]
- nitrosoureas [ATC Code]
- other alkylating agents [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Antineoplastic Alkylating Agent [NCIt concept]
Indexing information
- 1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea [MeSH Supplementary Concept]
- 2-(2-chloroethyl)-N-methyl-1,2-bis(methylsulfonyl)-N-nitrosohydrazinecarboxamide [MeSH Supplementary Concept]
- JDE52 [MeSH Supplementary Concept]
- MDX-1203 [MeSH Supplementary Concept]
- N-(2-chloroethyl)-2-methyl-1,2-bis(methylsulfonyl)-N-nitrosohydrazinecarboxamide [MeSH Supplementary Concept]
- melflufen [MeSH Supplementary Concept]
Ne pas confondre avec
- anticarcinogenic agents [MeSH Descriptor]
Record concept(s)
- antineoplastic agents, alkylating [MeSH concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea [MeSH Supplementary Concept]
- 14-O-phosphonooxymethyltriptolide disodium salt [MeSH Supplementary Concept]
- Bendamustine Hydrochloride [MeSH Descriptor]
- CC 1065 [MeSH Supplementary Concept]
- DU 86 [MeSH Supplementary Concept]
- Duocarmycins [MeSH Descriptor]
- KW 2189 [MeSH Supplementary Concept]
- N-acetyl-duocarmycin [MeSH Supplementary Concept]
- SL-1 mustard-quinoline conjugate [MeSH Supplementary Concept]
- Temozolomide [MeSH Descriptor]
- Trabectedin [MeSH Descriptor]
- U 76073 [MeSH Supplementary Concept]
- U 76074 [MeSH Supplementary Concept]
- acridine mustard [MeSH Supplementary Concept]
- adozelesin [MeSH Supplementary Concept]
- altretamine [MeSH Descriptor]
- aniline mustard [MeSH Descriptor]
- bizelesin [MeSH Supplementary Concept]
- busulfan [MeSH Descriptor]
- carbazilquinone [MeSH Descriptor]
- carmustine [MeSH Descriptor]
- carzelesin [MeSH Supplementary Concept]
- chlorambucil [MeSH Descriptor]
- cyclophosphamide [MeSH Descriptor]
- dacarbazine [MeSH Descriptor]
- dianhydrogalactitol [MeSH Descriptor]
- dipin [MeSH Supplementary Concept]
- duocarmycin A [MeSH Supplementary Concept]
- duocarmycin B1 [MeSH Supplementary Concept]
- duocarmycin B2 [MeSH Supplementary Concept]
- duocarmycin SA [MeSH Supplementary Concept]
- estramustine [MeSH Descriptor]
- ethoglucid [MeSH Descriptor]
- ethyl methanesulfonate [MeSH Descriptor]
- fotrin [MeSH Supplementary Concept]
- ifosfamide [MeSH Descriptor]
- irofulven [MeSH Supplementary Concept]
- isophosphamide mustard [MeSH Supplementary Concept]
- lomustine [MeSH Descriptor]
- mannomustine [MeSH Descriptor]
- mechlorethamine [MeSH Descriptor]
- melphalan [MeSH Descriptor]
- methyl methanesulfonate [MeSH Descriptor]
- mitobronitol [MeSH Descriptor]
- mitolactol [MeSH Descriptor]
- nitrogen mustard compounds [MeSH Descriptor]
- peptichemio [MeSH Descriptor]
- phosphoramide mustards [MeSH Descriptor]
- pipobroman [MeSH Descriptor]
- prednimustine [MeSH Descriptor]
- pyrindamycin A [MeSH Supplementary Concept]
- pyrindamycin B [MeSH Supplementary Concept]
- semustine [MeSH Descriptor]
- tallimustine [MeSH Supplementary Concept]
- thiotepa [MeSH Descriptor]
- treosulfan [MeSH Supplementary Concept]
- triaziquone [MeSH Descriptor]
- triethylenemelamine [MeSH Descriptor]
- triethylenephosphoramide [MeSH Descriptor]
- triptolide [MeSH Supplementary Concept]
- trofosfamide [MeSH Supplementary Concept]
- uracil mustard [MeSH Descriptor]
- yatakemycin [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Antineoplastic Alkylating Agent [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients